dpp4 vs glp 1 GLP-1 Series Part 1: Utilization drives decline in DPP-4 inhibitors, increase in SGLT2s among competitive drug classes dpp-4 inhibitor with glp-1 receptor

Please contact our sales team for the latest information

For example, cyanocobalamin can be risky for people with a condition called Leber's disease, as it might harm the optic nerve

Zhao R, Zhao M, Xu Z

Gut microbiota and oral contraceptive use in overweight and obese patients with polycystic ovary syndrome

CMS specifies that only 28-day or 30-day supplies are covered per fill, and that switching between covered GLP-1 drugs triggers a new prior authorization

Legal Framework FDAs announcement renews focus on the boundaries between traditional pharmacy compounding under Section 503A, bulk compounding under 503B and drug manufacturing requiring FDA approval